Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;2(1):44-9.
doi: 10.4103/2279-042X.114091.

Side effects of antineoplastic and immunomodulating medications reported by European consumers

Lise Aagaard  1 , Ebba Holme Hansen  2
Affiliations

Side effects of antineoplastic and immunomodulating medications reported by European consumers

Lise Aagaard et al. J Res Pharm Pract. 2013 Jan.

Abstract

Objective: To characterize adverse drug reactions (ADRs) reported by European (EU) consumer for antineoplastic and immunomodulating medications.

Methods: ADRs reported by consumers of antineoplastic and immunomodulating medications (anatomical therapeutic chemical [ATC]) group L from 2007 to 2011 and located in the EU ADR database, EudraVigilance, were analyzed. Data were categorized with respect to age and sex, category, and seriousness of reported ADRs and medications. The unit of analysis was one ADR.

Findings: We located 9649 ADRs reported for antineoplastic and immunomodulating medications, which approximately 15% of were serious, including 26 deaths. Less than 5% of ADRs were reported in children. Totally 73% of ADRs were reported for women and 27% for men. The majority of ADRs were of the type "general disorders and administration site conditions" (54% of total ADRs), followed by "skin and subcutaneous disorders" (7% of total ADRs), and "infections and infestations" (6% of total ADRs). Reports encompassed medicines from the therapeutic groups: Imunosupressants (ATC group L04) (90% of all ADRs), immunostimulants (ATC group L03) (6% of all ADRS), and antineoplastic agents (ATC group L01) (4% of all ADRs). Many ADRs were reported for etanercept (Enbrel(®)), Interferon beta (Betaferon(®)/Extavia(®)), and imatinib (Glivec(®)) with only few being serious.

Conclusion: In general, consumers reported a high number of ADRs from the use of antineoplastic and immunostimulant medications and many of these were classified as non-serious. This indicates that consumers are interesting in reporting ADRs, but since the investigated substances potentially have the risk of causing many ADRs, we expected a higher number of serious ADRs.

Keywords: Adverse drug reactions; antineoplastic agents; consumers; eudravigilance; immunomodulating agents; pharmacovigilance.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Similar articles

See all similar articles

Cited by

References

    1. Aagaard L, Strandell J, Melskens L, Petersen PS, Holme Hansen E. Global patterns of adverse drug reactions over a decade: Analyses of spontaneous reports to VigiBase™. Drug Saf. 2012;35:1171–82. - PubMed
    1. Hansen EH. Technology assessment in a user perspective–Experiences with drug technology. Int J Technol Assess Health Care. 1992;8:150–65. - PubMed
    1. Aagaard L, Hansen EH. Information about ADRs explored by pharmacovigilance approaches: A qualitative review of studies on antibiotics, SSRIs and NSAIDs. BMC Clin Pharmacol. 2009;9:4. - PMC - PubMed
    1. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: A review of published literature and international experience. Br J Clin Pharmacol. 2007;63:148–56. - PMC - PubMed
    1. Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependency and suicidal behaviour with paroxetine. Int J Risk Saf Med. 2003;16:5–19.